

DISTRICT OFFICE  
1915 EYE ST NW  
WASHINGTON, DC 20006

LAW OFFICES OF  
**DAVID E. PRICE**  
13520 ORIENTAL ST  
ROCKVILLE, MD 20853  
-----  
TEL (202) 536-5191

MONACO OFFICE  
SUITE #1, 17 BLVD DE SUISSE  
MONACO 98000

LONDON OFFICE  
ONE GREAT CUMBERLAND PLACE  
MARBLE ARCH, LONDON, W1H7AL

ISRAEL OFFICE  
DIAMOND TOWER, 28TH FLOOR  
3A JABOTINSKI RD., RAMAT-GAN 52520

[TopTier.eu](http://TopTier.eu)

June 28, 2012

OTC Markets, Inc.  
304 Hudson Street  
2nd Floor  
New York, NY 10013

Re: **Nouveau Life Pharmaceuticals, Inc.**  
**Sufficiency of Adequate Current Information**

Dear OTC Markets Group,

I have been retained by Nouveau Life Pharmaceuticals, Inc. (NOUV) a Nevada corporation (the "Issuer"), for the purpose of rendering this letter to you with respect to the information publicly disclosed by the Issuer to you and published in the OTC Disclosure and News Service. OTC Markets Inc. is entitled to rely on this letter in determining whether the Issuer has made adequate current information publicly available regarding the Issuer and the common stock of the Issuer (the "Securities") within the meaning of Rule 144(c)(2) promulgated under the Securities Act of 1933, as amended (the "Securities Act"). I hereby consent to having this letter posted by the Issuer, and to have it published, accompanying their disclosure in the OTC Markets News Service. I hereby represent that I am a U.S. resident and that I am licensed to practice law in the United States in the state of Maryland as well as all federal Courts of the District of Columbia. I am permitted to practice before the Securities and Exchange Commission (the "Commission") and I have not been prohibited from practice before the Commission. In addition, I hereby represent that neither I, nor my firm, are currently under investigation by any federal or state regulatory authority for any violation of federal or state securities laws.


In preparing this letter, I have examined such corporate records and other documents and such questions of law as I considered necessary or appropriate for the purposes of rendering this letter; including the Articles of Incorporation and Bylaws as well as: a) the Quarterly Report & Disclosure Statement, as well as the Interim Financial Report encompassing the unaudited Financial Statements as of March 31<sup>st</sup>, 2012, filed with OTC Markets Inc. on May 30<sup>th</sup> & 31<sup>st</sup>, 2012. As to matters of fact in this letter, I have relied upon information from public officials, officers of the Issuer and other sources, which sources I believed to be reliable. In such examination, I have assumed the genuineness of all signatures set forth on each document, the authenticity of all original documents and the conformity to original documents of all copies of such documents as may have been supplied to us during the course of my examination.

In issuing this letter, I represent as follows:

1. That the Issuer Disclosure posted on the OTC Disclosure and News Service and publicly available with regard to the Issuer (i) constitutes "adequate current public information" concerning the Securities and the Issuer and "is available" within the meaning of Rule 144(c)(2) under the Securities Act, (ii) includes all of the information that a broker-dealer would be required to obtain from the Issuer to publish a quotation for the Securities under Rule 15c2-11 under the Securities Exchange Act of 1934 (the "Exchange Act"), (iii) complies as to form with the OTC Markets Guidelines for Providing Adequate Current Information, which are located on the Internet at [www.OTCMarkets.com](http://www.OTCMarkets.com).
2. That the financial statements of the Issuer contained in the Issuer Disclosure were not audited and are prepared by Melissa Walker. M. Walker has an extensive background as an entrepreneur and management consultant to Fortune 100 companies where she gained experience preparing financial statements. She is familiar with all of the operations of Nouvea Life Pharmaceuticals. The financial statements are not audited.
3. That the issuer's Transfer Agent is Standard Registrar & Transfer Co-, 125 South 1840 East, Draper, Utah, 84020, 801 571-8844. The current issued and outstanding shares of the company is 899,999,733 as of this date. This Transfer Agent is registered by the SEC.
4. That I have (i) personally met with management of the Issuer, (ii) reviewed the Issuer Disclosure, as amended, published by the Issuer on the OTC Disclosure & News Service and (iii) discussed the Issuer Disclosure with management.
5. That to the best of my knowledge, after inquiry of management and the Board of Directors of the Issuer, that neither the Issuer, nor any of its officers and/or directors, or any 5% shareholder is currently under investigation by any federal or state regulatory authority for any violation of federal or state securities laws.

The opinions set forth herein are expressed as of the date hereof and remain valid so long as the documents, instruments, records and certificates I have examined and relied upon as noted above, are unchanged and the assumptions I have made, as noted above, are valid. While this letter is intended exclusively for use by OTC Markets, Inc., the same is hereby granted full and complete rights and permission without any future request to publish this letter as part of "OTCMarkets.com" for viewing by the public and regulatory agencies.

Sincerely yours,

A handwritten signature in blue ink, appearing to read "David E. Price", with a stylized flourish at the end.

David E. Price, Esq.

DEP/mc

cc, Ms. Melissa Walker, CEO